tetano
Editor, Senior Moderator
Med Clin (Barc)
. 2020 May 27;S0025-7753(20)30283-9.
doi: 10.1016/j.medcli.2020.04.018. Online ahead of print.
Effectiveness of Corticoid Pulses in Patients With Cytokine Storm Syndrome Induced by SARS-CoV-2 Infection
[Article in English, Spanish]
Jos? Luis Callejas Rubio[SUP] 1 [/SUP], Juan de Dios Luna Del Castillo[SUP] 2 [/SUP], Javier de la Hera Fern?ndez[SUP] 3 [/SUP], Emilio Guirao Arrabal[SUP] 4 [/SUP], Manuel Colmenero Ruiz[SUP] 5 [/SUP], Norberto Ortego Centeno[SUP] 6 [/SUP]
Affiliations
Abstract
Introduction: Cytokine storm syndrome (CSS) is a serious complication of COVID-19 patients. Treatment is tocilizumab. The use of glucocorticoids (GC) is controversial. In other very similar CSS, such as macrophage activation syndrome (MAS) and hemophagocytic syndrome (HFS), the main treatment are corticosteroids. Our objective is to evaluate the efficacy of GC in the CSS by COVID-19.
Patients: We included 92 patients with CSS associated to COVID-19 who received GC, GC, and tocilizumab and only tocilizumab. We determine CSS markers. We evaluated mortality, intubation, and a combined variable.
Results: In all cases the percentages of events were lower in the group of patients with GC was administered. The hazard ratio of the final variables with GC versus the group in which only tocilizumab was administered was lower as CGs were considered, with statistical significance for survival.
Discussion: The early use of GC pulses could control SLC, with a lower requirement to use tocilizumab and a decrease in events such as intubation and death.
Keywords: Coronavirus COVID-19; Cytokine release synddrome; Hemofagoc?tico; Hemophagocytic; S?ndrome de liberaci?n de citocinas.
. 2020 May 27;S0025-7753(20)30283-9.
doi: 10.1016/j.medcli.2020.04.018. Online ahead of print.
Effectiveness of Corticoid Pulses in Patients With Cytokine Storm Syndrome Induced by SARS-CoV-2 Infection
[Article in English, Spanish]
Jos? Luis Callejas Rubio[SUP] 1 [/SUP], Juan de Dios Luna Del Castillo[SUP] 2 [/SUP], Javier de la Hera Fern?ndez[SUP] 3 [/SUP], Emilio Guirao Arrabal[SUP] 4 [/SUP], Manuel Colmenero Ruiz[SUP] 5 [/SUP], Norberto Ortego Centeno[SUP] 6 [/SUP]
Affiliations
- PMID: 32532461
- DOI: 10.1016/j.medcli.2020.04.018
Abstract
Introduction: Cytokine storm syndrome (CSS) is a serious complication of COVID-19 patients. Treatment is tocilizumab. The use of glucocorticoids (GC) is controversial. In other very similar CSS, such as macrophage activation syndrome (MAS) and hemophagocytic syndrome (HFS), the main treatment are corticosteroids. Our objective is to evaluate the efficacy of GC in the CSS by COVID-19.
Patients: We included 92 patients with CSS associated to COVID-19 who received GC, GC, and tocilizumab and only tocilizumab. We determine CSS markers. We evaluated mortality, intubation, and a combined variable.
Results: In all cases the percentages of events were lower in the group of patients with GC was administered. The hazard ratio of the final variables with GC versus the group in which only tocilizumab was administered was lower as CGs were considered, with statistical significance for survival.
Discussion: The early use of GC pulses could control SLC, with a lower requirement to use tocilizumab and a decrease in events such as intubation and death.
Keywords: Coronavirus COVID-19; Cytokine release synddrome; Hemofagoc?tico; Hemophagocytic; S?ndrome de liberaci?n de citocinas.